Tricida Inc., of South San Francisco, said it closed its public offering of 6.44 million shares at $36 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 840,000 shares for total gross proceeds of approximately $231.8 million. (See BioWorld, March 29, 2019.)